Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 1, 2003, Pages 360-362

  Fattorini, Lanfranco ^a   Tan, Dejiang ^a   Iona, Elisabetta ^a   Mattei, Maurizio ^b   Giannoni, Federico ^a   Brunori, Lara ^a   Recchia, Simona ^a   Orefici, Graziella ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; SPARFLOXACIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; EXPERIMENTAL INFECTION; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; DRUG THERAPY, COMBINATION; ETHIONAMIDE; FLUOROQUINOLONES; MALE; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; QUINOLINES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 0037224238     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.1.360-362.2003     Document Type: Article

References (18)

1. Alvirez-Freites, E. J., J. L. Carter, and M. H. Cynamon. 2002. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46:1022-1025.
2. Coletsos, P. J. 1970. Experimental comparative study of the concentration of cycloserine in the serum and viscera in conventional laboratory animals and in the monkey. Scand. J. Respir. Dis. Suppl. 71:40-50.
3. Cynamon, M. H., S. P. Klemens, C. A. Sharpe, and S. Chase. 1999. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 43:1189-1191.
4. Fattorini, L., E. Iona, M. L. Ricci, O. F. Thoresen, G. Orrù, M. R. Oggioni, E. Tortoli, C. Piersimoni, P. Chiaradonna, M. Tronci, G. Pozzi, and G. Orefici. 1999. Activity of 16 antimicrobial agents against drug-resistant strains of Mycobacterium tuberculosis. Microb. Drug Resist. 5:265-270.
5. Heifets, L. B. 1991. Antituberculous drugs: activity in vitro, p. 13-57. In L. B. Heifets (ed.), Drug susceptibilities in the chemotherapy of mycobacterial infections. CRC Press, Inc., Boca Raton, Fla.
6. Inderlied, C. B., and M. Salfinger. 1999. Antimicrobial agents and susceptibility tests, p. 1601-1623. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th edition. American Society for Microbiology, Washington, D.C.
7. Iseman, M. 2000. Drug-resistant tuberculosis, p. 323-353. In M. Iseman (ed.), A clinician guide to tuberculosis. Lippincott Williams & Wilkins, Baltimore, Md.
8. Jagannath, C., H. S. Allaudeen, and R. L. Hunter. 1995. Activities of poloxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo. Antimicrob. Agents Chemother. 39:1349-1354.
9. Ji, B., N. Lounis, C. Maslo, C. Truffot-Pernot, P. Bonnafous, and J. Grosset. 1998. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42:2066-2069.
10. Klemens, S. P., M. S. DeStefano, and M. H. Cynamon. 1993. Therapy of multidrug-resistant tuberculosis: lessons from studies with mice. Antimicrob. Agents Chemother. 37:2344-2347.
11. Lounis, N., A. Bentoucha, C. Truffot-Pernot, B. Ji, R. J. O'Brien, A. Vernon, G. Roscigno, and J. Grosset. 2001. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob. Agents Chemother. 45:3482-3486.
12. Majumdar, S., and S. K. Basu. 1991. Killing of intracellular Mycobacterium tuberculosis by receptor-mediated drug delivery. Antimicrob. Agents Chemother. 35:135-140.
13. NCCLS. 2001. Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes. Tentative standard M24-T2 - second edition, vol. 20, no. 26. NCCLS, Wayne, Pa.
14. Panà, C., and L. Lenzini. 1970. Experimental research on cycloserine. Scand. J. Respir. Dis. Suppl. 71:76-85.
15. Pozzi, G., M. Meloni, E. Iona, G. Orrù, O. F. Thoresen, M. L. Ricci, M. R. Oggioni, L. Fattorini, and G. Orefici. 1999. rpoB mutations in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Italy. J. Clin. Microbiol. 37:1197-1199.
16. Tahaoglu, K., T. Torun, T. Sevim, G. Atac, A. Kir, L. Karasulu, I. Ozmen, and N. Kapakli. 2001. The treatment of multidrug-resistant tuberculosis in Turkey. N. Engl. J. Med. 345:170-174.
17. Trnka, L., P. Mison, K. Bartmann, and H. Otten. 1988. Anti-tuberculous drugs: experimental evaluation of efficacy. Handb. Exp. Pharmacol. 84:31-225.
18. Yoshimatsu, T., E. Nuermberger, S. Tyagi, R. Chaisson, W. Bishai, and J. Grosset. 2002. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob. Agents Chemother. 46:1875-1879.